[Pharmacological trials evaluating treatment options for neuropsychiatric symptoms in post-COVID. A narrative review].

Autor:	Lejay N; Centre Leenaards de la mémoire, Département des neurosciences cliniques, Centre hospitalier universitaire vaudois et Université de Lausanne, 1011 Lausanne., Salvioni Chiabotti P; Centre Leenaards de la mémoire, Département des neurosciences cliniques, Centre hospitalier universitaire vaudois et Université de Lausanne, 1011 Lausanne., Ducrot A; Service de médecine de premier recours, Hôpitaux universitaires de Genève, 1211 Genève., Allali G; Centre Leenaards de la mémoire, Département des neurosciences cliniques, Centre hospitalier universitaire vaudois et Université de Lausanne, 1011 Lausanne., Nehme M; Service de médecine de premier recours, Hôpitaux universitaires de Genève, 1211 Genève.
Jazyk:	francouzština
Zdroj:	Revue medicale suisse [Rev Med Suisse] 2023 May 17; Vol. 19 (827), pp. 984-991.
DOI:	10.53738/REVMED.2023.19.827.984
Abstrakt:	Post-COVID prevalence's is estimated at 10 % in the general population. The neuropsychiatric symptoms, which are frequent (up to 30 %), can severely affect the quality of life of patients affected by this condition, notably by significantly reducing their working ability. To date, no pharmacologic treatment is available for post-COVID, apart from symptomatic treatments. A large number of pharmacological clinical trials for post-COVID are underway since 2021. A number of these trials targets neuropsychiatric symptoms, based on the various underlying pathophysiological hypotheses. The objective of this narrative review is to provide an overview of these ongoing trials targeting neuropsychiatric symptoms in post-COVID. Competing Interests: Les auteurs n’ont déclaré aucun conflit d’intérêts en relation avec cet article
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu